Reflecting on Sun Pharma’s acquisition of Ranbaxy, Ameesh Masurekar, Director, AIOCD AWACS, comments that this deal is the largest ever consolidation of the Indian pharmaceutical industry and harks back to the 90s where Indian MNCs used to acquire global MNC franchisee. It will have domestic as well as global implications. In the new pecking order, the combined entity becomes number one, with a shade short of 10 per cent market share.
Monthly market share without bonus units of the combined entity is 9.43 per cent. The chart depicts the current rank – with yellow indicating previous ranking of the stand-alone companies. The market share of Indian pharma companies versus MNC is now in the ratio of 77.2 versus. 22.8, compared to the previous 73.4 : 26.6. Masurekar observes that this should again rebut unnecessary opposition to allowing brownfield FDI in India pharma.
As far as ranking among therapy area, of the the top 10 therapy areas, which account for 90 per cent of the Indian pharma market – the combined entity Sun + Ranbaxy has reached a very dominant position by being within the top four ranks amongst all segments. It tops in cardio, pain/analgesics, gynec and neuro/CNS, whereas Sun earlier enjoyed top spot only in Neuro/CNS. It is in second position in two of them (Gastro and Vit/Min/Nut).
EP News Bureau – Mumbai
- Advertisement -
